Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.64 |
---|---|
High | 1.69 |
Low | 1.57 |
Bid | 1.60 |
Offer | 1.66 |
Previous close | 1.64 |
Average volume | 215.30k |
---|---|
Shares outstanding | 1.41m |
Free float | 1.24m |
P/E (TTM) | -- |
Market cap | 2.26m USD |
EPS (TTM) | -2,217.58 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
- Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
- Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
- Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
- Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
- Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
- Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
- Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
- Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
More ▼